In­ves­ti­ga­tors sound a safe­ty alarm af­ter 2 pa­tients die of heart con­di­tion fol­low­ing check­point com­bo

Check­point in­hibitors like Keytru­da and Op­di­vo quick­ly achieved leg­endary sta­tus as break­through can­cer ther­a­pies with broad, block­buster roles to play on the mar­ket. But in a new study pub­lished in the New Eng­land Jour­nal of Med­i­cine, in­ves­ti­ga­tors have spot­light­ed rare cas­es in which check­point pa­tients have died or been af­flict­ed by heart trou­ble. And there’s ev­i­dence that a T-cell dri­ven re­ac­tion threat­ens a very small group of pa­tients tak­ing the drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER